Clinical Trial

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to see if the combination of rituximab and venetoclax is effective in treating participants with untreated Marginal Zone Lymphoma (MZL). The names of the study drugs involved in this study are: * Venetoclax (a type of inhibitor) * Rituximab (a type of antibody)
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-07-15; most recent amendment 2026-03-12.
Status change: Not Yet Recruiting → Recruiting 2026-03-12
Trial Details
NCT Number NCT06510309
Lead Sponsor Gottfried von Keudell, MD PhD
Collaborators: AbbVie
Conditions Lymphoma, Marginal Zone Lymphoma, MZL
Enrollment 33 participants
Start Date 2026-02-11
Primary Completion 2028-10 (estimated)
Study Completion 2031-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-13